Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1 Resistant Melanoma

Using an aggressive melanoma tumor model, the authors targeted PSGL-1 in tumor-bearing mice and found increased effector CD4+ and CD8+ T cell responses and decreased regulatory T cells in tumors.